Same product. Same dose. Different biology. Different experience.

Here’s a situation that probably sounds familiar. Two people use the same cannabis product from the same bottle, with the same cannabinoid ratio and the same labeled dose. One says, “That was perfect.” The other says, “Good Lord, what did you give me?”

We tend to assume somebody did something wrong. Maybe the dose wasn’t measured correctly, maybe one person is unusually sensitive, or maybe somebody didn’t follow directions. Sometimes that’s true. But there’s another possibility that’s considerably more interesting: the medicine may be the same, but the people aren’t.

We measure milligrams because milligrams are measurable. Five milligrams of THC is five milligrams of THC, and precise dosing matters. But the number on the label tells us how much cannabinoid was administered. It doesn’t tell us what happens after it enters a living human being with their own genetics, metabolism, medications, age, health, previous cannabis exposure, receptor history, sleep, stress and food intake.

In pharmacology, pharmacokinetics describes what the body does to a drug—how it’s absorbed, distributed, metabolized and eliminated. Pharmacodynamics describes what the drug does to the body. Put those together and it becomes easier to understand why identical milligrams don’t guarantee identical experiences.

Cannabis adds another major variable: route of administration. Inhaled THC reaches circulation quickly. Oral THC takes a different route through the digestive system and liver, where some is converted into 11-hydroxy-THC, an active metabolite that can contribute substantially to the experience. Oral absorption can also vary, which helps explain the famous edible sequence of “Nothing’s happening, I’ll take another one,” followed an hour later by negotiations with the furniture.

Genetics can matter too. THC is metabolized in part by liver enzymes including CYP2C9 and CYP3A4, and human research has shown that genetic variation affecting CYP2C9 can significantly change exposure to oral THC. Two people can swallow the same amount while their bodies process it differently.

The label didn’t change. The biology did.

Previous cannabis exposure changes the equation again because the endocannabinoid system adapts. Frequent THC exposure can produce tolerance, and brain-imaging research has found reduced CB1 receptor availability associated with chronic cannabis use that can move back toward control levels during abstinence. That means even within the same person, today’s 10 milligrams may not produce the same response that 10 milligrams produced six months ago.

This is where saying “everybody is different” isn’t enough. The useful question is different how? Age, medications, liver function, genetics, previous exposure, route of administration, food and health status can all influence cannabinoid response. The condition we’re trying to influence matters too. Someone using cannabinoids for persistent pain isn’t necessarily starting from the same biological state as someone using them for sleep, nausea or anxiety.

And then there’s the endocannabinoid system itself. The ECS isn’t simply a collection of receptors waiting around for cannabis to arrive. It’s an active signaling network involving our own endocannabinoids—including anandamide (AEA) and 2-arachidonoylglycerol (2-AG)—along with CB1 and CB2 receptors and the enzymes that produce and break down those signaling molecules.

That system is dynamic. Stress can alter it. Sleep and circadian timing interact with it. Repeated THC exposure can change receptor responsiveness. Disease and aging can alter aspects of endocannabinoid signaling. So THC or CBD doesn’t enter an empty biological container; it enters an existing biological conversation.

Cannabis didn’t invent the endocannabinoid system. It walked into a conversation that was already happening.

This changes the question from “What does THC do?” to something more useful: “What does this dose of THC do in this person, under these conditions, at this point in time?”

CBD complicates things further because its pharmacology is quite different from THC. CBD has relatively low affinity for the classical cannabinoid receptor binding sites and influences numerous other molecular targets. It can also interact with drug-metabolizing enzymes, so clinically meaningful medication interactions are possible at sufficient doses. Calling THC and CBD both “cannabinoids” doesn’t make them interchangeable. The plant may package them together; pharmacology doesn’t care about branding.

This is why start low and go slow makes biological sense. When individual response varies, gradually finding the lowest dose that produces the desired effect while monitoring tolerability is more rational than assuming everyone needs the same number.

But there’s another piece that’s just as important: know what you’re trying to accomplish. If the goal is better sleep, define better sleep. If it’s pain relief, determine whether pain, function or both improve. Otherwise, cannabinoid dosing can become chasing sensations instead of measuring useful outcomes. With THC in particular, feeling more intoxicated doesn’t necessarily mean receiving greater therapeutic benefit.

Now add one more variable we’ve recently been discussing: time. Endocannabinoid signaling changes across the circadian cycle. Sleep affects the ECS, and the hormonal, metabolic and neurological environment at 9 AM isn’t identical to the environment at 9 PM. That raises an emerging question we’ve called cannabinoid chronotherapy—whether cannabinoid administration might eventually be optimized partly according to biological timing.

We don’t yet have enough human clinical evidence to build a universal cannabinoid dosing clock, but the question itself reinforces the larger point of this article. A person isn’t only biologically different from someone else; they’re different from themselves across time.

The future of cannabinoid medicine probably won’t come from discovering one perfect THC:CBD ratio that works for everybody. It’s more likely to come from better understanding the product, dose, route, timing, therapeutic objective and individual receiving it.

That’s personalized cannabinoid medicine without the marketing fluff.

The Biology

THC and CBD undergo absorption, distribution, metabolism and elimination that can vary considerably between people. Route of administration strongly affects cannabinoid pharmacokinetics, while genetic variation in enzymes such as CYP2C9 can alter THC exposure. Repeated THC exposure can also produce pharmacodynamic adaptation, including changes in CB1 receptor availability associated with tolerance.

The endocannabinoid system adds another layer because it is itself dynamic. Endocannabinoid signaling and receptor responsiveness can change with stress, previous cannabinoid exposure, sleep, disease and biological timing.

A cannabinoid dose therefore can’t be understood solely as a number of milligrams.

Key Takeaway

Precise dosing matters, but precision isn’t the same thing as uniformity. Two people receiving identical cannabinoid doses can experience different effects because absorption, metabolism, genetics, medications, tolerance, health status and the ECS itself can differ.

So instead of asking only “What’s the right dose?”, we need another question beside it:

“The right dose for whom?”

Coming Up Next…

The Adaptive Human #4 — When the Same Dose Stops Working

Next we’ll remove the second person entirely. Same person, same product, same dose—but six months later it doesn’t work the way it used to.

What changed?

The person did.

Next we’ll look at cannabinoid tolerance, CB1 receptor adaptation and why simply increasing the dose isn’t always the smartest response when biology has adapted to the signal.